BioRestorative Therapies (BRTX) Non-Current Debt (2010 - 2021)
BioRestorative Therapies' (BRTX) quarterly Non-Current Debt came in at $191030.0 in Q4 2021, down 95.53% YoY from $4.3 million in Q4 2020, and down 7.19% on a QoQ basis from $205828.0 in Q3 2021.
BioRestorative Therapies (BRTX) Non-Current Debt (2010 - 2021) Analysis & Trends
BioRestorative Therapies (BRTX) has 12 years of Non-Current Debt data on file, last reported at $191030.0 in Q4 2021.
- Quarterly Non-Current Debt fell 95.53% year-over-year to $191030.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $191030.0 (down 95.53% YoY) and the FY2021 annual result came in at $191030.0, down 95.53% from the prior year.
- Non-Current Debt eased to $191030.0 in Q4 2021, from $205828.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $5.7 million in Q2 2019 to a low of $25000.0 in Q4 2019.
- A 5-year average of $2.6 million and a median of $3.3 million in 2017 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2019 — Non-Current Debt tumbled 96.38% — and 2020, when it jumped 16980.93%.
- Tracing BRTX's Non-Current Debt over 5 years: stood at $3.7 million in 2017, then slumped by 85.69% to $523894.0 in 2018, then sank by 95.23% to $25000.0 in 2019, then jumped by 16980.93% to $4.3 million in 2020, then tumbled by 95.53% to $191030.0 in 2021.
- The last three Non-Current Debt figures came in at $191030.0 (Q4 2021), $205828.0 (Q3 2021), and $5.0 million (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.92 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.73 Bn | 50.59 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 8.96 Bn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.01 Mn | 17,964.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 191,030.00 |
| Sep 30, 2021 | 205,828.00 |
| Jun 30, 2021 | 5.03 Mn |
| Mar 31, 2021 | 4.48 Mn |
| Dec 31, 2020 | 4.27 Mn |
| Mar 31, 2020 | 4.20 Mn |
| Dec 31, 2019 | 25,000.00 |
| Sep 30, 2019 | 157,143.00 |
| Jun 30, 2019 | 5.70 Mn |
| Mar 31, 2019 | 4.00 Mn |
| Dec 31, 2018 | 523,894.00 |
| Sep 30, 2018 | 4.34 Mn |
| Jun 30, 2018 | 368,718.00 |
| Mar 31, 2018 | 3.78 Mn |
| Dec 31, 2017 | 3.66 Mn |
| Sep 30, 2017 | 2.93 Mn |
| Jun 30, 2017 | 120,120.00 |
| Mar 31, 2017 | 2.08 Mn |
| Dec 31, 2016 | 2.16 Mn |
| Jun 30, 2016 | 499,341.00 |